TrialEuropean journal of nuclear medicine and molecular imaging2021

RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer.

Désirée Deandreis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.